['DRUGS KNOWN TO PROLONG QT INTERVAL (E.G., CLASS IA AND CLASS III ANTIARRHYTHMIC AGENTS).', 'QUALAQUIN PROLONGS QT INTERVAL, ECG ABNORMALITIES INCLUDING QT PROLONGATION AND TORSADES DES POINTES. AVOID CONCOMITANT USE ( 5.3 ).', 'OTHER ANTIMALARIALS (E.G., HALOFANTRINE, MEFLOQUINE).', 'ECG ABNORMALITIES INCLUDING QT PROLONGATION. AVOID CONCOMITANT USE ( 5.3 , 7.2 ).', 'CYP3A4 INDUCERS OR INHIBITORS', 'ALTERATION IN PLASMA QUININE CONCENTRATION. MONITOR FOR LACK OF EFFICACY OR INCREASED ADVERSE EVENTS OF QUININE ( 7.1 ).', 'CYP3A4 AND CYP2D6 SUBSTRATES', 'QUININE IS AN INHIBITOR OF CYP3A4 AND CYP2D6. MONITOR FOR LACK OF EFFICACY OR INCREASED ADVERSE EVENTS OF THE CO-ADMINISTERED DRUG ( 7.1 ).', 'DIGOXIN', 'INCREASED DIGOXIN PLASMA CONCENTRATION ( 5.8 , 7.1 ).']